Trial record 1 of 1 for:
NCT01895452
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01895452 |
|
Recruitment Status :
Completed
First Posted : July 10, 2013
Results First Posted : August 25, 2017
Last Update Posted : August 25, 2017
|
Sponsor:
Alkermes, Inc.
Information provided by (Responsible Party):
Alkermes, Inc.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is an extension of a previous study (ALK9072-003EXT). The purpose of this study is to continue to evaluate the long-term safety and durability of effect of ALKS 9072 in subjects with stable schizophrenia, and to allow subjects who are doing well on ALKS 9072 to continue treatment.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Schizophrenia | Drug: ALKS 9072, Low Dose Drug: ALKS 9072, High Dose | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 291 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia |
| Study Start Date : | July 2013 |
| Actual Primary Completion Date : | June 2016 |
| Actual Study Completion Date : | June 2016 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Schizophrenia
MedlinePlus related topics:
Schizophrenia
| Arm | Intervention/treatment |
|---|---|
| Experimental: ALKS 9072, Low Dose |
Drug: ALKS 9072, Low Dose
Intramuscular injection, given monthly |
| Experimental: ALKS 9072, High Dose |
Drug: ALKS 9072, High Dose
Intramuscular injection, given monthly |
Primary Outcome Measures :
- Number and Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to 12 months ]This measure includes all incidences, including those that occurred >5%.
Secondary Outcome Measures :
- Change in Baseline of Positive and Negative Syndrome Scale (PANSS) Total Score Over Time [ Time Frame: Up to 12 months ]This scale consists of symptom constructs (7 positive, 7 negative, 16 general psychopathology), each to be rated on a 7-point Likert-type scale of severity with 1 being absent to 7 being extreme. Minimum scores (best outcome) equals 30 (total scale); maximum scores (worst outcome) equals 210 (total scale). Change is calculated between the baseline visit and the subject's last visit in the treatment period.
- Mean Change From Baseline to Endpoint in Clinical Global Impression - Severity (CGI-S) Over Time [ Time Frame: Up to 12 months ]The CGI-S is a 7-point scale that requires the clinician to assess how mentally ill the patient is in a specific point in time. Results indicate participants evaluated at one of the following categories: "1: normal, not at all ill"; "2: borderline mentally ill"; "3: mildly ill"; "4: moderately ill"; "5: markedly ill"; "6: severely ill"; and "7: among the most extremely ill patients". Results indicate a change in CGI-S score from baseline to Day 365 based on the observed data. Change is calculated between the baseline visit and the subject's last visit in the treatment period.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Completed the treatment period of Study ALK9072-003EXT
- Continues to require chronic treatment with an antipsychotic medication
- Continues to reside in a stable living situation
- Continues to have an identified reliable informant
Exclusion Criteria:
- Abnormal clinical laboratory value, vital sign, or electrocardiogram (ECG) finding during participation in Study ALK9072-003EXT that was clinically relevant and related to study drug
- Missed more than 1 scheduled study visit during participation in the preceding Study ALK9072-003EXT
- Has a significant or unstable medical condition that would preclude safe completion of the current study
- Subject is pregnant or breastfeeding
- Subject expects to be incarcerated, or has pending legal action which may impact compliance with study participation or procedures
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01895452
Locations
Show 57 study locations
Sponsors and Collaborators
Alkermes, Inc.
Investigators
| Study Director: | Robert Risinger, MD | Alkermes, Inc. |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Alkermes, Inc. |
| ClinicalTrials.gov Identifier: | NCT01895452 |
| Other Study ID Numbers: |
ALK9072-003EXT2 |
| First Posted: | July 10, 2013 Key Record Dates |
| Results First Posted: | August 25, 2017 |
| Last Update Posted: | August 25, 2017 |
| Last Verified: | July 2017 |
Keywords provided by Alkermes, Inc.:
|
Schizophrenia |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders |